PMID- 24338736
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20221207
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 34
IP  - 2
DP  - 2014 Feb
TI  - Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese 
      patients with type 2 diabetes mellitus.
PG  - 131-9
LID - 10.1002/phar.1379 [doi]
AB  - STUDY OBJECTIVE: To investigate the associations of NOS1AP rs12742393 
      polymorphism with the risk of type 2 diabetes mellitus (T2DM) and repaglinide 
      therapeutic efficacy in Chinese patients with T2DM. DESIGN: Prospective 
      case-control study. SETTING: Academic medical center. PATIENTS: A total of 300 
      patients with T2DM and 200 healthy volunteers were enrolled to identify NOS1AP 
      rs12742393 genotypes using the polymerase chain reaction-restriction fragment 
      length polymorphism assay. Eighty-four patients with various genotypes were 
      randomly selected to receive oral repaglinide as a single-agent therapy 
      (3 mg/day) for 8 weeks. MEASUREMENTS AND MAIN RESULTS: Anthropometric 
      measurements and fasting plasma glucose (FPG), postprandial plasma glucose, 
      hemoglobin A1c , fasting serum insulin (FINS), postprandial serum insulin, 
      homeostasis model assessment for insulin resistance (HOMA-IR), triglyceride, 
      total cholesterol, low-density lipoprotein-cholesterol, and high-density 
      lipoprotein-cholesterol tests were obtained before and after repaglinide 
      treatment. The risk C allelic frequency of NOS1AP rs12742393 was higher in 
      patients with T2DM than in healthy volunteers (p<0.001). Patients with T2DM and 
      genotypes AA and AC at NOS1AP rs12742393 had a significant reduction in FPG 
      (mmol/l) compared with those with genotype CC (p<0.01). Patients with CC 
      homozygotes and AC heterozygotes had a greater increase in FINS (mU/l) than those 
      with wild-type AA (p<0.05). In addition, the carriers of genotype CC at NOS1AP 
      rs12742393 had higher differential values of HOMA-IR compared with genotypes AC 
      and AA carriers (p<0.001). The effects of repaglinide treatment on FPG (p<0.01), 
      FINS (p<0.05) and HOMA-IR (p<0.001) were reduced in patients with T2DM carrying 
      the NOS1AP rs12742393 risk C allele compared with the AA genotype carriers. 
      CONCLUSION: The NOS1AP rs12742393 polymorphism is associated with therapeutic 
      efficacy of repaglinide in Chinese T2DM patients.
CI  - (c) 2013 Pharmacotherapy Publications, Inc.
FAU - Wang, Tao
AU  - Wang T
AD  - Key Laboratory of New Drugs and Clinical Application, Xuzhou Medical College, 
      Xuzhou, China; Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical 
      College, Xuzhou, China.
FAU - Wang, Yan
AU  - Wang Y
FAU - Lv, Dong-Mei
AU  - Lv DM
FAU - Song, Jin-Fang
AU  - Song JF
FAU - Lu, Qian
AU  - Lu Q
FAU - Gao, Xing
AU  - Gao X
FAU - Zhang, Fan
AU  - Zhang F
FAU - Guo, Hao
AU  - Guo H
FAU - Li, Wei
AU  - Li W
FAU - Yin, Xiao-Xing
AU  - Yin XX
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20131213
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Blood Glucose)
RN  - 0 (Carbamates)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (NOS1AP protein, human)
RN  - 0 (Piperidines)
RN  - 668Z8C33LU (repaglinide)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*genetics
MH  - Adult
MH  - Alleles
MH  - Asian People/genetics
MH  - Blood Glucose/drug effects
MH  - Carbamates/*therapeutic use
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/genetics
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Piperidines/*therapeutic use
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Prospective Studies
OTO - NOTNLM
OT  - NOS1AP rs12742393
OT  - genetic polymorphism
OT  - repaglinide
OT  - type 2 diabetes mellitus
EDAT- 2013/12/18 06:00
MHDA- 2015/01/21 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - 10.1002/phar.1379 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2014 Feb;34(2):131-9. doi: 10.1002/phar.1379. Epub 2013 Dec 13.